Graham worked in NHS mental health services for 15 years; eight of those years as a consultant psychiatrist in a psychiatric hospital in Brighton & Hove. He has an MSc in Neuroscience from Kings College London and trained with the Imperial College Psychedelic Research Group to work as an assistant guide on the psilocybin vs escitalopram depression trial (Psilodep 2).
He has helped organise and facilitate psychedelic integration groups in Brighton since 2019 and has worked as an associate editor for a special edition of Frontiers in Psychiatry on the potential clinical application of psychedelics. He is a member of the Advisory Council with The Institute of Psychedelic Therapy and co-chairs Academic Circle groups for IPT members/affiliates.
In 2020, he left the NHS to work full-time as a trial psychiatrist and psychedelic guide for Small Pharma’s DMT-assisted psychotherapy trials for depression. Phase I and Phase IIa trials have now been completed. Graham has contributed to the development of a therapist training programme for the DMT trials, having co-produced a psychedelic therapy framework for working with DMT.
He also works as an advisor and writer for Lumenate; a company that turns your phone into a strobe light for inducing altered states of consciousness. He is a mentor for the MIND Foundation augmented psychotherapy training programme and works in private psychiatry practice in Brighton.
Colloquium Presentation: 22 March 2024, 3.30-5pm (speaking in person)
Title: DMT- Assisted psychotherapy for Depression ( TRACE – DMT Framework )
Graham and Michelle will share their experience of working with DMT-assisted psychotherapy as a potential treatment for depression. They will describe the Phase I and IIa trials and share some of the experiences of healthy volunteers and patients in the trials. They hope to provide an insight into the participant journey through the trials and the broad nature of their psychedelic experiences. They will present the main findings from both trials whilst offering reflection on their experience of working with DMT as a potential therapeutic tool.